Market accessCompany release

Inspire Medical Q3 revenue falls 7.9% as new single-lead HGNS CPT codes approved

🇺🇸 Inspire Medical Systems, Inc. (INSP) · Mon 02 Nov 2026

Inspire Medical Systems reports a Q3 2026 revenue decline and net loss, while the AMA approves Category I CPT codes for single-lead hypoglossal nerve stimulation from January 2028.

Inspire Medical Systems reported third-quarter 2026 results on 2 November, with revenue down 7.9% year over year to $206.7 million. The company attributed the decline mainly to coding and reimbursement challenges in the United States.

The company posted a net loss of $24.4 million for the quarter. That figure included charges linked to restructuring and a legal settlement.

Separately, the American Medical Association's CPT Editorial Panel approved new Category I codes for single-lead hypoglossal nerve stimulation (HGNS). The codes cover Inspire V, the company's system for obstructive sleep apnoea, and take effect on 1 January 2028. As context, Category I CPT codes are the standard procedure codes used in the US to report medical services and are widely used in billing and payer coverage processes.

Inspire also narrowed its 2026 revenue guidance to a range of $850 million to $860 million. The summary provided does not give further detail on the previous range or on the quarter's operating drivers.

What it means for your team

  • Market-access teams should note that the new single-lead HGNS codes do not take effect until 1 January 2028, leaving a long interim period of existing coding arrangements.
  • The company links its revenue decline mainly to US coding and reimbursement challenges, underlining how billing codes can affect uptake of implantable devices.
  • Teams tracking sleep apnoea device reimbursement should monitor how payers handle Inspire V coding ahead of the 2028 effective date.

Company's press release (SEC filing): Inspire Medical Systems, Inc. ↗

Article written by VigiEye from the official source (Inspire Medical Systems, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →